About Alzheon
Alzheon is a private company based in Framingham, Massachusetts. It has reported $251,258,071 raised in ten offerings on Form D since July 2013. Its chief executive is Martin Tolar, M.D., Ph.D..
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | Sep 10, 2026 | $78,797,184of $499.9M target | 3 | $26.2M | EquityRule 506(b) | Form D ↗ |
| Feb 27, 2024 | Mar 12, 2024amended Feb 10, 2025 | $126,259,938of $150.0M target | 76 | $1.6M | EquityRule 506(c) | Form D/A ↗2 earlier filings |
| Dec 27, 2022 | Jan 11, 2023 | $1,703,768of $50.0M target | 6 | $283K | EquityRule 506(b) | Form D ↗ |
| Sep 16, 2020 | Sep 30, 2020 | $2,432,016of $50.0M target | 5 | $486K | EquityRule 506(b) | Form D ↗ |
| Apr 25, 2019 | Jan 15, 2020 | $6,163,716fully sold | 13 | $474K | Equity, Conversion of Convertible Promissory NotesRule 506(b) | Form D ↗ |
| May 25, 2017 | Jun 9, 2017amended Sep 5, 2018 | $19,801,820fully sold | 81 | $244K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Feb 4, 2016 | Feb 26, 2016 | $1,300,000of $5.0M target | 3 | $433K | Debt, OptionsRule 506(b) | Form D ↗ |
| Jul 13, 2015 | Jul 27, 2015 | $6,905,000fully sold | 26 | $265K | Debt, OptionsRule 506(b) | Form D ↗ |
| Dec 30, 2014 | Jan 9, 2015amended Feb 25, 2015 | $7,344,629target not set | 60 | $122K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jul 23, 2013 | Jul 31, 2013amended Dec 16, 2013 | $550,000fully sold | 8 | $68,750 | Debt, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Total, ten offerings | $251,258,071 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Alzheon's Form D filed Sep 10, 2026.
Earlier filings also listed Glenn Pauly (chief commercial officer, last listed Feb 2025), Noel Dunn (director, last listed Sep 2020), David Nikodem, Ph.D. (director, last listed Jan 2020), Scott Minick (director, last listed Sep 2018), Martin Tolar (chief executive officer and director, last listed Sep 2018), Jean-Pierre Garnier (director, last listed Sep 2018), Franz Hefti (director, last listed Sep 2018) and Dennis Langer (director, last listed Sep 2018).
Sources
- SECALZHEON, INC. Form D/A, filed Jan 2, 2025
- SECALZHEON, INC. Form D, filed Mar 12, 2024
- SECALZHEON, INC. Form D, filed Jun 9, 2017
- SECALZHEON, INC. Form D, filed Jan 9, 2015
- SECALZHEON, INC. Form D, filed Jul 31, 2013
- SECALZHEON, INC. filing history
- CompanyBoard of directors
- CompanyManagement team
- CompanyValiltramiprosate biomarker publication announcement
- CompanyHippocampal volume publication announcement
- CompanyAPOLLOE4 trial publication announcement